…lizumab and NEDA (P1348); cognition and Dimethyl fumarate (P1396); DMF long-term data (P1397) Network meta-analysis: P1394 Recommendations: Initial DMT choice (P1351) Emerging treatments: Evobrutinib (P1358); Biotin (P1399) Interesting items: • Placebo cohorts (P1140) • Cognitive relapses (P1155) • Driving ability (P1308) • Vitamin D and NfL (P1347) • Beyond NEDA (P1415) Canadian research: Prodrome (P1124; P1153); Comparing DMTs (P1125); ADEM (P11…

…ngitudinal (P946) Phase III data: Siponimod (P750); Alemtuzumab (P974) Long-term data: Natalizumab (P1013); Fingolimod (P1014); Ocrelizumab (P1015); Beta-interferon-1b (P1016) Anti-CD20 and immunoglobulins: P979, P1010 NEDA and MEDA: loss of MEDA (P1030); prognostic value (P1050); DMTs (P1070) Biotin: P1002, P1003 Network meta-analysis: P981 Interesting items: • DMT outcomes (P812) • Use of gadolinium (P901) • PML and ocrelizumab (P970) • Nocebo e…

…Phase III data: Siponimod (P382, P435); Cladribine (P385, P624, P633) Long-term data: Alemtuzumab (P645, P651); Teriflunomide (P646); Dimethyl fumarate (P647); Glatiramer acetate (P656) MSBase studies: MSSS and disability (P434); Cladribine (P661) Interesting items: • Prevalence of hypogammaglobulinemia (P407) • Patient-determined disease steps (P433) • Siponimod vs. Fingolimod (P622) • Ocrelizumab safety (P648) • Hepatitis B vaccination (P671) C…